Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMF vs Azathioprine in Treatment-Naive Autoimmune Hepatitis
NCT06650124Phase 3Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mycophenolate mofetil in autoimmune hepatitis (AIH) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Biochemical Remission at 24 weeks. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT06650124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650124.